Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Section 3 of 6

Product information and disease description

399 evidence topics · 168 sources

Product description

Phase of product development

Summary: development stage and regulatory timing

Lanifibranor is an investigational oral product in phase 3 development for adults with noncirrhotic MASH and F2 to F3 fibrosis. The last participant completed the final 72-week visit of the NATiV3 phase 3 trial, and NATiV3 topline results were expected in the fourth quarter of 2026. Inventiva states that, if the results are favorable, it anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA granted Fast Track designation and, in October 2020, Breakthrough Therapy designation, and the Chinese NMPA granted Breakthrough Therapy designation in December 2023. Company guidance for NATiV3 topline results changed across successive releases: from the second half of 2024 to the second half of 2025, the first half of 2026, the beginning of the second half of 2026, the second half of 2026, and the fourth quarter of 2026.

Regulatory status: Submission planned; NDA for accelerated approval planned for the first half of 2027
EU PRIME designation

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
FieldQuoted record
International nonproprietary name (Latin)“lanifibranorum”
International nonproprietary name (English)“lanifibranor”
Chemical name“4-[1-(1,3-benzothiazole-6-sulfonyl)-5-chloro-1H-indol- 2-yl]butanoic acid”
Functional description“peroxisome proliferator-activated receptors (PPAR) agonist”
Molecular formula“C19H15ClN2O4S2”
CAS registry number“927961-18-0”
INN list“Proposed INN: List 116”
Brand name

No evidence found.

Dosage forms and strengths
Commercial strengths and package sizes

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Proposed labeling

No evidence found.

Pharmacology
Mechanism of action
Pharmacodynamics
Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin

“The phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 28-day study evaluated lanifibranor in participants with T2DM who were on metformin monotherapy (Figure 1)” (opens the source at this quote in a new tab)

“Lanifibranor (400, 800, and 1400 mg) consistently induced dose- and time-related increases in total and HMW adiponectin (Figure 4), which is indicative of PPARγ engagement” (opens the source at this quote in a new tab)

“Exposures of about 50 µg·h/mL for area under the curve from time zero to the last measurable concentration (AUC0-τ) and about 7 µg/mL for the maximal concentration (Cmax) resulted in more than 200% increase for the percent change from baseline total adiponectin” (opens the source at this quote in a new tab)

“Dose-related improvements in insulin, pro-insulin, and insulin resistance were observed with lanifibranor, with a significant reduction in pro-insulin with 1400 mg versus placebo.” (opens the source at this quote in a new tab)

“Reductions in average and postprandial blood glucose were observed at 1400 mg (Table 2), which were consistent with the PPARγ insulin-sensitizing mechanism” (opens the source at this quote in a new tab)

“Lanifibranor 800 and 1400 mg showed significant (P<0.05) change from baseline in high-density lipoprotein (HDL) cholesterol and triglycerides compared with placebo (Figure 5 and Table 2)” (opens the source at this quote in a new tab)

“At Day 28, lanifibranor showed no fluid-retention signals (pedal edema, ankle foot volume, ankle circumference, or body-weight increase) versus placebo, with no changes in hematology, albumin, or brain natriuretic peptide (BNP; Table 3)” (opens the source at this quote in a new tab)

Mean (SD) percent change from baseline at day 28Lanifibranor 400 mg (n=17)Lanifibranor 800 mg (n=15)Lanifibranor 1400 mg (n=15)Placebo (n=14)
Triglycerides“–19.7 (33.9)”“–20.8 (23.5)”“–31.7 (31.2)”“–5.81 (27.6)”
HDL-C“13.4 (15.3)”“16.7 (17.2)”“27.7 (25.9)”“2.52 (12.2)”
Pro-insulin“–26.7 (35.6)”“–21.1 (45.0)”“–37.4 (26.3)”“–3.28 (49.9)”
Mean (SD) value reported for change from baseline at day 28Lanifibranor 400 mg (n=17)Lanifibranor 800 mg (n=15)Lanifibranor 1400 mg (n=15)Placebo (n=14)
Ankle foot volume, cm3“3.75 (14.51)”“–5.31 (15.51)”“3.91 (11.14)”“–5.42 (11.07)”
Body weight change at Day 28, kg“0.55 (1.97)”“0.11 (1.72)”“0.94 (2.05)”“–0.36 (2.68)”
Hemoglobin, g/L“–5.63 (4.81)”“–5.04 (6.75)”“–5.96 (5.55)”“–3.70 (5.29)”
Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE

“This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With placebo only 10% had moderate, and none high increase (Supplementary Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Adiponectin is a pleiotropic adipokine and PPARγ downstream mediator, while PPARα activity may affect adiponectin signaling through receptor upregulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fasting high density lipoprotein cholesterol (HDL-C) increased significantly at treatment week 4 (TW4), maintained until EOT: patients receiving lanifibranor 1200 mg and 800 mg had an AMD at EOT of 0.10 mmol/L (95%CI: 0.03 to 0.16, p = 0.003, equivalent to 3.9 mg/dL) and 0.16 mmol/L (95%CI: 0.09 to 0.22, p < 0.001, equivalent to 6.2 mg/dL), respectively (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Systolic BP did not change significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Renal impairment: dedicated pharmacokinetic study

No evidence found.

Hepatic impairment: dedicated pharmacokinetic study

No evidence found.

Pediatric population: pediatric studies

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Lanifibranor
Published results of drug-drug interaction study 337HVPK21014

No evidence found.

Effects of Lanifibranor on other drugs
Dosing and administration
Dosage
Commercial dose and dose adjustment for special populations

No evidence found.

Administration
Access and distribution
Commercialization rights in Greater China: CTTQ
Specialty pharmacy or distribution network

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Lanifibranor on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Approved and phase 3 competitors named by Inventiva in its annual report

“In March 2024, Madrigal received FDA approval of Rezdiffra for the treatment of patients with MASH with moderate to advanced liver fibrosis and received a conditional marketing authorization from the European Commission in August 2025.” (opens the source at this quote in a new tab)

“For example, Boehringer Ingelheim, Eli Lilly, Akero Therapeutics (a subsidiary of Novo Nordisk), GSK and Roche and 89bio are also evaluating their respective investigational MASH medications in Phase 3 clinical trials in patients with non-cirrhotic MASH and in patients with cirrhotic MASH.” (opens the source at this quote in a new tab)

“Other companies, including Sagimet, Boston Pharmaceuticals, Altimmune, AstraZeneca, Eli Lilly, NorthSea, Terns, Viking, BMS, Pfizer, and Regeneron and Gilead Sciences have drug candidates for the treatment of MASH that are in less advanced clinical or pre-clinical development stages.” (opens the source at this quote in a new tab)

“We may lose lanifibranor’s Fast Track Designation if the FDA concludes that Rezdiffra and/or Wegovy addresses the unmet medical need for patients with MASH.” (opens the source at this quote in a new tab)

“For example, lanifibranor has caused weight gain in certain patients and the potential for this side effect may, if approved, lead patients to prefer a GLP-1 agent for the treatment of MASH.” (opens the source at this quote in a new tab)

Resmetirom: month 12 histology in Trial 1 (NCT03900429), 888 F2 and F3 participants, missing biopsy counted as nonresponse
Endpoint at month 12Placebo (N=294)REZDIFFRA 80 mg (N=298)REZDIFFRA 100 mg (N=296)
Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist A (%)“13”“27”“36”
Difference vs. placebo (95% CI), Pathologist ANot applicable“14 (8, 20)”“23 (16, 30)”
Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist B (%)“9”“26”“24”
Difference vs. placebo (95% CI), Pathologist BNot applicable“17 (11, 23)”“15 (9, 21)”
Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist A (%)“15”“23”“28”
Difference vs. placebo (95% CI), Pathologist ANot applicable“8 (2, 14)”“13 (7, 20)”
Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist B (%)“13”“23”“24”
Difference vs. placebo (95% CI), Pathologist BNot applicable“11 (5, 17)”“11 (5, 17)”
Semaglutide: week 72 histology in Study 11 (NCT04822181), 800 F2 and F3 participants, reference-based multiple imputation
Endpoint at week 72Placebo (N=266)WEGOVY injection (N=534)Difference vs. placebo (95% CI)
Resolution of steatohepatitis and no worsening of liver fibrosis, response rate (%)“34”“63”“29 (21, 36)”
Improvement in liver fibrosis and no worsening of steatohepatitis, response rate (%)“22”“37”“14 (8, 21)”
Resolution of steatohepatitis and improvement in liver fibrosis, response rate (%)“16”“33”“17 (10, 23)”
Pegozafermin: acquisition of 89bio by Roche, agreement in September 2025 and tender offer completed in October 2025
Pegozafermin: ENLIVEN phase 2b week 24 histology, full analysis population with multiple imputation

“In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], −9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Missing end-point data (for 28 patients) were imputed with the use of multiple imputation by means of logistic regression with all collected outcomes. The full analysis population included all the enrolled patients who had undergone randomization and received at least one dose of pegozafermin or placebo and who had confirmed fibrosis stage F2 or F3 (indicating moderate or severe fibrosis) and a nonalcoholic fatty liver disease activity score of at least 4 at baseline, as assessed on independent review by a three-pathologist panel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Survodutide: phase 2 week 48 histology in F1 to F3 MASH, 293 participants who received at least one dose
Tirzepatide: SYNERGY-NASH phase 2 week 52 histology in F2 or F3 MASH, 190 randomized with missing biopsies imputed

“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pemvidutide: PERFORMA phase 3 trial in F2 to F3 MASH initiated in August 2026
FieldQuoted record
Sponsor“Altimmune, Inc.”
Status“Recruiting”
Study start (actual)“2026-07-30”
Primary completion (estimated)“2028-12”
Enrollment (estimated)“1800”
Arms“Pemvidutide 1.8 mg”
Arms“Pemvidutide 2.4 mg”
Pemvidutide: IMPACT phase 2b week 24 histology in F2 or F3 MASH, intention-to-treat population

“IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The dual primary endpoints were MASH resolution without worsening of fibrosis or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001), and 45 (52%) of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0·0001). Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1·2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0·59), and 30 (36%) of 85 patients in the 1·8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0·27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this timepoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Cross-trial comparison of adiponectin change: lanifibranor, resmetirom, efruxifermin, and pegozafermin, with the authors’ caveat that results may not be comparable
Product (trial, time point)DoseAbsolute change in adiponectin from baseline at end of treatment, µg/ml
Lanifibranor (NATIVE, 24 weeks)“800mg”“+ 11.95 (8.97 to14.94)”
Lanifibranor (NATIVE, 24 weeks)“1200mg”“+ 17.12 (14.29 to 19.96)”
Resmetirom (MAESTRO-NASH, 52 weeks)“80mg”“+ 0.86 (0.19)”
Resmetirom (MAESTRO-NASH, 52 weeks)“100mg”“+ 1.1 (0.19)”
Efruxifermin (HARMONY, 24 weeks)“28mg”“+ 1.4(0.74 to 2.08)”
Efruxifermin (HARMONY, 24 weeks)“50mg”“+ 3.0(2.34 to 3.71)”
Pegozafermin (ENLIVEN, 24 weeks)“15mg”“+ 1.1(0.7)”
Pegozafermin (ENLIVEN, 24 weeks)“30mg”“+ 1.1(0.3)”
Pegozafermin (ENLIVEN, 24 weeks)“44mg”“+ 1.2 (0.4)”
Network meta-analysis of 29 randomized trials including lanifibranor, with the authors’ stated limitations

“We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 29 randomized controlled trials (n=9324) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Data from eligible studies were extracted as intention-to-treat (ITT) analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pegozafermin (RR: 3.46, CrI: 1.54–11.15), cilofexor + firsocostat (RR: 2.67, CrI: 1.05–8.13), denifanstat (RR: 1.94, CrI: 1.04–4.04), survodutide (RR: 1.86, CrI: 1.18– 3.28), obeticholic acid (RR: 1.85, CrI: 1.30–2.75), tirzepatide (RR: 1.77, CrI: 1.17–2.94), resmetirom (RR: 1.64, CrI: 1.27–2.20), and semaglutide (RR: 1.51, CrI: 1.23–1.90) were statistically better than placebo in achieving ≥1 stage of fibrosis improvement without worsening MASH (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pegozafermin (RR: 8.65, CrI: 2.63–59.42), survodutide (RR: 6.62, CrI: 3.13–17.97), tirzepatide (RR: 4.65, CrI: 2.31–10.66), efruxifermin (RR: 3.51, CrI: 1.83–8.17), liraglutide (RR: 3.23, CrI: 1.11–14.17), vitamin E + pioglitazone (RR: 3.03, CrI: 1.31–9.04), resmetirom (RR: 2.54, CrI: 1.86–3.55), pioglitazone (RR: 2.29, CrI: 1.41–4.03), denifanstat (RR: 2.03, CrI: 1.04–4.72), semaglutide (RR: 1.87, CrI: 1.60–2.24), and lanifibranor (RR: 1.93, CrI: 1.30–3.02) were statistically better than placebo in achieving MASH resolution without worsening fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“First, we acknowledge the modest number of trials with direct comparisons between pharmacological therapies, and the small number of trials for each agent; hence, most comparisons between treatments were based on indirect evidence; head-to-head trials versus other drugs should be considered to validate our findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Comparability between trials was further limited by their heterogeneity in design and population (eg, demographics and comorbidities).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Prevalence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Natural history, survival, and mortality
Progression to cirrhosis and all-cause mortality in non-cirrhotic MASH F2 and F3: US TARGET-NASH cohort, 2,378 participants

“Among the 2378 patients included in this analysis, 48% had MASH cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the 1425 patients with non-cirrhotic MASH, there were 982 patients in the F0–F1 cohort, 281 patients in the F2 cohort, and 162 patients in the F3 cohort (Supplemental Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Incidence rates of cirrhosis increased from 0.34/100PM in the F0–F1 cohort to 1.24/100PM in the F2 cohort and 6.62/100PM in the F3 cohort (Table 5). Unadjusted risk of progressing to cirrhosis was highest among those with F3 (HR, 95% CI; 18.66, 10.97–31.73) and 3.74 times higher with F2 (HR, 95% CI; 3.74, 2.00–6.98) versus F0–F1 (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All-cause mortality was associated with disease severity and incidence rates increased from 0.14/100PM in the F0–F1 cohort to 0.3/100PM in the F2 cohort, 0.42/100PM in the F3 cohort, 2.02/100PM in the compensated cirrhosis cohort and 4.62/100PM in the decompensated cirrhosis cohort (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This analysis was supported by Novo Nordisk Inc., Plainsboro, NJ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

US deaths from chronic liver disease and cirrhosis of all causes, 2024
MeasureValue
Number of deaths“52,274”
Deaths per 100,000 population“15.4”
Cause of death rank“9”
Pathophysiology
Diagnosis
Primary risk assessment with FIB-4: thresholds, AASLD 2023 practice guidance

“When the fibrosis-4 index (FIB-4) is <1.3, patients can be followed in the primary care setting and reassessed periodically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients older than age 65, a FIB-4 cutoff of > 2.0 should be used. FIB-4 has low accuracy in those under age 35; thus, secondary assessment should be considered in those <35 with increased metabolic risk or elevated liver chemistries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with FIB4 ≥ 1.3, a secondary assessment should be done [preferentially vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF) initially] or the patient referred for further risk stratification (if being seen in a nongastroenterology/hepatology setting). Direct referral to gastroenterology/hepatology should be considered in those with aminotransferases persistently (> 6 mo) above normal to exclude other causes of liver disease or when FIB4 > 2.67 due to the increased risk of clinically significant fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, a change in FIB-4 status category from low risk (< 1.3) to intermediate risk (1.3–2.67) to high risk (> 2.67) may be used to assess clinical progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Screening with FIB-4 in type 2 diabetes or prediabetes: ADA Standards of Care 2026

“4.22a Screen adults with type 2 diabetes or with prediabetes, particularly those with obesity or other cardiometabolic risk factors or established cardiovascular disease, for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“4.23 Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A value of <1.3 is considered low risk of having advanced fibrosis (F3–F4) and for developing adverse liver outcomes, while ≥1.3 is considered as having a higher probability of at-risk MASH clinically significant fibrosis (≥F2) and increased risk of adverse liver outcomes. A value of >2.67 confers a high risk of having advanced fibrosis (F3–F4), and referral to the liver specialist is warranted without additional testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In individuals with diabetes ≥65 years of age, higher cutoffs for FIB-4 have been recommended (1.9–2.0 rather than ≥1.3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Rule-out and rule-in cut-offs of non-invasive tests for fibrosis and at-risk MASH, EASL-EASD-EASO 2024 guideline
Selection of resmetirom candidates with non-invasive tests: AASLD 2024 guidance update

“There are no FDA-approved noninvasive tests to diagnose MASH with F2-F3 or to monitor response to pharmacotherapy.” (opens the source at this quote in a new tab)

“Notably, the FDA-approved label does not require liver biopsy to confirm the diagnosis of fibrotic MASH. While MASH can only be definitively diagnosed by histologic examination, patient selection in practice is based on evidence of steatosis and fibrosis as determined by NILDA methodologies among persons with cardiometabolic risk factors without other causes of steatosis, notably alcohol consumption of more than 20 g/d for women and more than 30 g/d for men.” (opens the source at this quote in a new tab)

“In general, imaging-based NILDAs, such as liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or magnetic resonance elastography (MRE),” (opens the source at this quote in a new tab)

“In the MAESTRO-NASH trial, participants were screened with VCTE and those with LSM >8.5 kPa in whom liver histology demonstrated MASH with F2-F3 were enrolled. Among enrolled participants, the median (interquartile range) LSM by VCTE was 12 kPa (10-15 kPa) and the mean LSM by MRE was 3.5 kPa. The median (interquartile range) of the enhanced liver fibrosis score was 9.7 (9.2-10.4).” (opens the source at this quote in a new tab)

“For example, 50% of participants with biopsy-proven F2-F3 in the MAESTRO-NASH trial had LSM by VCTE that was outside the interquartile range of 10 kPa to 15 kPa.” (opens the source at this quote in a new tab)

Selection of semaglutide candidates with non-invasive tests: AASLD 2025 guidance update

“Semaglutide (Wegovy) candidates should have MASH with stages 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15–20 kPa), MRE (4.4–5 kPa), or ELF (10.5–11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of <150,000/mm3.” (opens the source at this quote in a new tab)

“Semaglutide is not approved as an indication for patients with MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3, and/or evidence of portal hypertension).” (opens the source at this quote in a new tab)

“A FIB-4 score below 1.3 excludes advanced fibrosis (F3 or greater) in 99% of all patients and 95% of patients with multiple cardiometabolic risks in the primary care setting.” (opens the source at this quote in a new tab)

“To be clear, FIB-4 should not be used as a single rule-in or rule-out test for semaglutide eligibility for patients with MASLD/MASH.” (opens the source at this quote in a new tab)

“The recommended range of 8–15 kPa included ~50% of the study population, while up to 19% of participants had LSM <8 kPa, and up to 32.5% of participants had LSM ≥15 kPa.” (opens the source at this quote in a new tab)

Clinical presentation - signs and symptoms
Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022

“We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fourteen prespecified individual physician-reported features of MASH were evaluated by the survey: fatigue, sleep disturbance, insomnia, general weakness, unexplained weight loss, hair loss, changes to personality, memory loss, jaundice, aching/discomfort in upper right abdomen, itchy skin, swelling in the legs/ankles/feet, tendency to bleed and bruise more easily, and swelling of the abdomen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 14 reported signs and symptoms, 11 were significantly associated with both physician-stated fibrosis stage and/or AASLD-derived risk category.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Physician-reported sign or symptom, n (%)Overall (n = 424)AASLD-derived low risk (n = 141)AASLD-derived indeterminate risk (n = 30)AASLD-derived high risk (n = 82)
None“167 (39.4)”View highlighted excerpt for this quote“58 (41.1)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“9 (11.0)”View highlighted excerpt for this quote
Constitutional symptoms: fatigue, sleep disturbance, and general weakness
Cognitive symptoms: memory loss and changes to personality
Signs of fluid retention, bleeding, and hepatic decompensation
Long-term morbidity
Burden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Humanistic burden and health-related quality of life
SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network
Fatigue and pruritus in 1,669 adults with NASH and bridging fibrosis or compensated cirrhosis, STELLAR 3 and 4 baseline

“were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All PRO scores of patients with fatigue were significantly impaired (mean up to −31% of a PRO range size in comparison to patients without fatigue).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All PROs were impaired (by up to −19% of a range size, all P < 0.01) in patients with NASH with pruritus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although patients with bridging fibrosis had higher median fatigue scores (indicative of less fatigue) than those with cirrhosis (5.0 [IQR 4.0‐5.8] vs. 4.7 [3.5‐5.7]; P = 0.0028), the difference does not meet the threshold of a minimal clinically important difference for domain scores of the CLDQ‐NASH (approximately 0.5 points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Patient-reported outcomes and fibrosis improvement in 392 adults with NASH and bridging fibrosis or compensated cirrhosis, phase 2 trial NCT03449446

“Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo‐controlled study of selonsertib, firsocostat, or cilofexor, alone or in two‐drug combinations (NCT03449446).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Baseline Physical Functioning (PF) and Bodily Pain of SF‐36 and Fatigue and Worry of CLDQ‐NASH were significantly lower in patients with cirrhosis (total CLDQ‐NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After 48 weeks of treatment, patients with ≥1‐stage fibrosis improvement without worsening of NASH experienced improvement in EQ‐5D and five out of six CLDQ‐NASH domains (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fibrosis regression was independently associated with greater improvements in PF and EQ‐5D scores, while NAS improvement was associated with improvement in fatigue and pruritus (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

CLDQ-MASH domain scores by histologic fibrosis stage (F3 to F4 versus F0 to F2) in adults with MASH
EQ-5D and CLDQ-NAFLD index by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study
Baseline mapped EQ-5D utility by fibrosis stage in 800 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, ESSENCE trial part 1
Baseline groupBaseline EQ-5D utility, mean (SD)
Fibrosis stage 2, semaglutide (n = 169)“0.783 (0.186)”View highlighted excerpt for this quote
Fibrosis stage 2, placebo (n = 81)“0.789 (0.190)”View highlighted excerpt for this quote
Fibrosis stage 3, semaglutide (n = 365)“0.792 (0.176)”View highlighted excerpt for this quote
Fibrosis stage 3, placebo (n = 185)“0.769 (0.194)”View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018

“In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, costs for patients with advanced fibrosis were higher (€3,983) than for those with early-stage fibrosis (€2,224).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A major share of indirect costs resulted from early retirement or stopping working (74%), followed by time off work in the previous 12 months (26%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patient indirect or productivity-related costs correlated positively with NASH severity, because patients with relatively more severe disease had to stop working (12% vs. 5% in patients with early-stage disease) or cited that their retirement was the result of NASH (13% vs. 5% in patients with early-stage disease)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Annual direct medical cost by liver health state, 2025 US dollars, payer-perspective model funded by a diagnostics manufacturer
All-cause annual costs by FIB-4 category in 6,743 US adults with NASH, linked electronic health record and claims data, 2016 to 2020
Health care resource use and work impairment in 136 US adults with NASH versus matched general population, 2016 National Health and Wellness Survey

“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In terms of HRU, there were more visits to an HCP (8.43 vs. 5.17, p < 0.001), ER visits (0.73 vs. 0.38, p = 0.021), and hospitalizations (0.43 vs. 0.21, p = 0.024) for NASH compared to the matched general population cohort (Fig. 3) and NASH patients reported more specialty visits (p’s < 0.05), for example, more general/family medicine provider visits (1.49 vs. 1.14, p = 0.040), hepatologist visits (0.10 vs. 0.02, p = 0.022), and gastroenterologist visits (0.38 vs. 0.12 p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Impairment of work and activity on WPAI was significantly higher for NASH patients compared to matched general population cohort, including absenteeism (17.0% vs. 9.2%, p = 0.041) and presenteeism (32.9% vs. 22.2%, p = 0.019), as well as overall work impairment (39.6% vs. 26.2%, p = 0.011), and activity impairment (44.7% vs. 30.8%, p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Work productivity and activity impairment by fibrosis risk category in 429 US adults with MASH, 2019 and 2022 physician and patient surveys
Economic impact of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis on families
Informal and professional caregiver costs by fibrosis stage in adults with NASH, United States and five European countries, GAIN study
Mean annual direct non-medical cost per patient (SD), patient-reportedEarly fibrosis (n = 546)Advanced fibrosis (n = 221)USA (n = 97)
Non-medical“€1,704 (5,785)”View highlighted excerpt for this quote“€4,661 (9,839)”View highlighted excerpt for this quote“€3,243 (7,685)”View highlighted excerpt for this quote
Economic impact of diagnostic testing
Fibrosis staging required for coverage of resmetirom or semaglutide: liver biopsy, VCTE, MRE, or ELF test, national commercial prior authorization policy
Unit costs of the ELF test, transient elastography, imaging, and liver biopsy in hepatology workup, 2025 US dollars, model funded by a diagnostics manufacturer
Lifetime costs of FIB-4 and ELF screening strategies with resmetirom treatment of F2 to F3 fibrosis in high-risk US primary care patients, model funded by a diagnostics manufacturer

“We developed a decision-analytic model for MASLD natural history and treatment to compare 6 noninvasive test strategies using Fibrosis-4 (FIB-4) and/or enhanced liver fibrosis (ELF) tests at varying cutoffs. Patients identified with significant fibrosis were referred for hepatology staging (biopsy and/or imaging-based), and eligible individuals were considered for Resmetirom ($47,400/y; mean duration: 1.6–1.8 year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sequential screening with ELF (cutoff 9.80) following indeterminate FIB-4 (1.3–2.67) was the most cost-effective, yielding 8.610 QALYs and $96,990 in lifetime costs at a $100,000/QALY threshold. ELF-alone screening at a 9.00 cutoff maximized QALYs and individuals treated but increased unnecessary referrals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Resmetirom treatment costs were obtained from Centers for Medicare & Medicaid Services ($47,400/y at the time of analysis) and applied exclusively to individuals with F2-3 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Five-year direct costs of FIB-4 followed by ELF or VCTE screening of all US adults living with diabetes, 2026 to 2030, study funded by test and drug manufacturers

“This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The Fibrosis‐4 (FIB‐4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration‐controlled transient elastography (VCTE) for confirmatory assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Over 5 years, the estimated costs of Strategy 1 ranged from R$0.7–1.3 billion for Brazil, €346–617 million for Germany, ¥80–172 billion for Japan, SAR 3.7–6.0 billion for the KSA, €591–949 million for Spain and $2.7–15.2 billion for the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Strategy 2 resulted in higher costs, ranging from R$1.2–2.0 billion for Brazil, €528–940 million for Germany, ¥121–262 billion for Japan, SAR 5.7–9.2 billion for the KSA, €0.9–1.4 billion for Spain and $4.1–23 billion for the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by Boehringer Ingelheim, Echosens and Novo Nordisk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Number of diagnostic tests and biopsy confirmation rate by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024

Approaches to treatment

Current treatment options and standard of care
Lifestyle intervention and weight loss
EASL-EASD-EASO guideline recommendations: weight loss targets, diet quality, and physical activity in adults with MASLD
Thyroid hormone receptor-beta agonists
EASL-EASD-EASO guideline recommendations: resmetirom in non-cirrhotic MASH with significant fibrosis

“If approved locally and dependent on the label, adults with non-cirrhotic MASH with significant liver fibrosis (stage ≥2) should be considered for treatment with resmetirom as a MASH-targeted therapy, as this treatment demonstrated histological efficacy on steatohepatitis and fibrosis in a large phase III registrational trial with an acceptable safety and tolerability profile (LoE 2, strong recommendation, consensus).” (opens the source at this quote in a new tab)

“Treatment with resmetirom, if approved locally, may be considered for individuals with MASLD who are non-cirrhotic and with documentation of either: (A) advanced fibrosis; (B) at-risk steatohepatitis with significant fibrosis (by liver biopsy, when available, or by non-invasive panels validated for that purpose); or (C) risk of adverse liver-related outcomes (e.g. by elastography- or biomarker-defined thresholds) (LoE 3, open recommendation, consensus).” (opens the source at this quote in a new tab)

“No MASH-targeted pharmacotherapy can currently be recommended for adults with MASH at the cirrhotic stage (LoE 5, weak recommendation, strong consensus).” (opens the source at this quote in a new tab)

“For individuals with MASLD undergoing therapy with resmetirom, data on sustainability of histological benefits, individual prediction of response, liver-related outcomes and long-term safety are not currently available (LoE 5, strong consensus).” (opens the source at this quote in a new tab)

Incretin-based therapies
Tirzepatide: SYNERGY-NASH phase 2 trial in MASH with F2 or F3 fibrosis, 190 randomized participants with missing week 52 biopsies imputed

“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pioglitazone and vitamin E
ADA Standards of Care recommendations 4.27a, 4.27b, and 4.30a: pioglitazone in adults with type 2 diabetes and MASH

“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the context of treating hyperglycemia in individuals with type 2 diabetes with MASLD, where the low cost of pioglitazone and any liver improvement would be an added benefit to glycemic management, these plans would be potentially cost-effective for the treatment of MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

PIVENS: pioglitazone 30 mg or vitamin E 800 IU vs placebo in 247 adults without diabetes, 96 weeks, intention-to-treat primary analysis

“We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary analysis was an intention-to-treat analysis in which the proportions of subjects in each active-treatment group (pioglitazone and vitamin E) in whom there was improvement in nonalcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P = 0.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“both agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for vitamin E and P = 0.12 for pioglitazone).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pioglitazone 45 mg/d for 18 months in 101 randomized participants with NASH and prediabetes or type 2 diabetes

“Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Single-center study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pioglitazone safety: weight gain, heart failure, fractures, and bladder cancer in guideline texts
Sodium-glucose cotransporter-2 inhibitors and other off-label therapies
Bariatric and metabolic surgery
SPLENDOR cohort: major adverse liver outcomes and cardiovascular events at 10 years after bariatric surgery in fibrotic NASH without cirrhosis
Limitations of current therapies
Summary

Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis, both under accelerated approval based on improvement of MASH and fibrosis. In the MAESTRO-NASH primary analysis population of 966 patients, NASH resolution with no worsening of fibrosis occurred in 25.9% (resmetirom 80 mg) and 29.9% (100 mg) compared with 9.7% (placebo), and fibrosis improvement by at least one stage in 24.2% and 25.9% compared with 14.2%. The EASL guideline states that evidence is limited to 52-week histological data, that about 70-80 % of participants did not respond according to histological criteria, and that there is no evidence to guide when to stop treatment. In the ESSENCE interim analysis of the first 800 patients at week 72, resolution of steatohepatitis occurred in 62.9% with semaglutide and 34.3% with placebo, and reduction in fibrosis in 36.8% and 22.4%; the AASLD semaglutide update states that 37.1% of treated participants did not resolve MASH and 63.2% did not have a reduction in fibrosis, and that available data do not identify predictors of response. No FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response to pharmacotherapy. Resmetirom and semaglutide have not been studied in combination or compared. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes and that no MASH-targeted pharmacotherapy can currently be recommended at the cirrhotic stage.

Other options have limits. Few patients (≤ 10%) achieve effective weight loss with structured interventions at 1 year, and fewer than half of these maintain it at 5 years; in one cohort, 88 of 293 participants (30%) lost 5% or more of their weight at week 52. Pioglitazone and vitamin E are not FDA approved for MASH, the EASL guideline does not recommend either as a MASH-targeted therapy, and in a 96-week trial in 247 adults without diabetes neither was associated with improvement in fibrosis scores; pioglitazone was associated with a mean weight gain of 4.7 kg at week 96, and its label states that thiazolidinediones cause or exacerbate congestive heart failure in some patients. The EASL guideline finds insufficient evidence to recommend SGLT2 inhibitors or metformin as MASH-targeted therapies. Metabolic surgery is not indicated solely for treatment of MASH, advanced fibrosis persisted in 47% of individuals in one post-surgery biopsy study, and in a cohort of 650 surgical patients with fibrotic NASH, 4 (0.6%) died from surgical complications within the first year.

Access and persistence are also limited. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated. In one cohort, 129 of 137 patients prescribed resmetirom (94.2%) required prior authorization, 33 (24.1%) prior authorization denials required appeal, and resmetirom was dispensed on average 22.7 days after prescription; in another cohort, 13 patients (16%) discontinued resmetirom after an average of 25.5 days, 11 because of adverse events. In company market research with 100 US MASH treaters, 85% of specialists described the greatest unmet needs as lack of effective, liver-directed therapies.

Place in treatment, anticipated use, and care setting
Summary

Lanifibranor is an investigational medicine that has not been approved by any regulatory authority. It is being evaluated in the phase 3 NATiV3 trial in patients with MASH with moderate and advanced fibrosis, and the manufacturer expects to report topline results in the fourth quarter of 2026. In the EASL guideline, management of MASLD consists of lifestyle modification and optimal management of comorbidities, including incretin-based therapies for type 2 diabetes or obesity, with resmetirom, if approved locally, considered as a MASH-targeted therapy for non-cirrhotic MASH with fibrosis stage 2 or higher; no MASH-targeted pharmacotherapy is recommended for the cirrhotic stage. The same guideline describes a phase IIb trial of lanifibranor with dose-dependent histological improvement of steatohepatitis and fibrosis and side effects of a 2.5% increase in weight, pedal oedema, and mild anaemia. For adults with type 2 diabetes and biopsy-proven MASH or high risk of liver fibrosis, the American Diabetes Association prefers a GLP-1 RA for glycemic management, allows pioglitazone plus a GLP-1 RA, and advises referral to a gastroenterologist or hepatologist for consideration of a thyroid hormone receptor-β agonist.

The American Diabetes Association states that MASH therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team, and the Cigna prior authorization policy for Rezdiffra requires prescribing by or in consultation with an endocrinologist, gastroenterologist, or hepatologist. About 14% of MAESTRO-NASH participants were receiving a GLP-1 RA, and the EASL guideline considers it reasonable to use resmetirom by the same criteria in these individuals; the AASLD resmetirom update states that data are insufficient to guide whether or when to start resmetirom in persons already taking therapies with potential MASH efficacy. Combination use of semaglutide 2.4 mg/week with resmetirom has not been studied, and another publication did not recommend upfront combination therapy and supported treatment consideration with resmetirom or semaglutide for noncirrhotic MASLD with liver stiffness of 10 to 20 kPa or ELF of 9.2 to 11.3. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription, mostly before resmetirom (33.8%), and 231 of the remaining 4524 (5.1%) were co-initiators.

The manufacturer describes lanifibranor as a once-daily oral therapy, plans to demonstrate its value as monotherapy and in combination, and states that NATiV3 assesses lanifibranor in combination with GLP-1 and SGLT2 inhibitors. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.

Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary

In the NATIVE trial at week 24, in the full analysis population with missing data handled by multiple imputation, a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) occurred in 55% of participants receiving lanifibranor 1200 mg (significant) and 48% receiving 800 mg (not significant), compared with 33% receiving placebo; resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%. The company topline release reported the primary end point in the ITT population as 49% (1200 mg, P=0.004), 41% (800 mg, P=0.061), and 27% (placebo). The trial publication states that fibrosis is the primary predictor of complications and death in NASH and that regression of fibrosis is associated with decreased risk of liver-related events.

Evidence linking fibrosis stage to outcomes comes from pooled cohort studies and models. Across cohort studies of biopsy-proven NAFLD, stage 3 to 4 fibrosis carried higher all-cause (HR 3.32) and liver-related mortality (HR 10.40) than stage 0 to 2. The estimated time to progress by one stage was 13.3 years from F2 and 22.2 years from F3, and the time to regress by one stage was 12.5 years from F3 and 20.4 years from F2. A US model estimated that a hypothetical therapy halting fibrosis progression in MASLD would reduce cases of decompensated cirrhosis by 11-39%, hepatocellular carcinoma by 10-34%, and liver-related deaths by 8-31%. The AASLD resmetirom update states that stabilization of fibrosis may portend important long-term benefits. The EASL guideline states that agents receiving accelerated approval for MASH must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, and hepatocellular carcinoma).